LONDON/ZURICH (Reuters) - Glivec (imatinib), which has dramatically improved survival prospects for some cancer patients, can interfere with bone development, according to U.S. researchers. Results of a study published this week in The New England Journal of Medicine indicated that the drug inhibits bone formation and resorption -- a process known as bone remodelling. Novartis has not found similar adverse effects in a large database it keeps of clinical trials and post-marketing data, though the study is interesting enough to warrant further research, said a spokesman for the drug maker Novartis AG.
